Direxion Daily S&P Biotech Bull 3X ETF
LABU
20 hedge funds and large institutions have $22.5M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2020 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 7 closing their positions.
41% more capital invested
Capital invested by funds: $15.9M → $22.5M (+$6.57M)
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
24% more call options, than puts
Call options by funds: $92.3M | Put options by funds: $74.2M
5% more funds holding
Funds holding: 19 → 20 (+1)
0.02% more ownership
Funds ownership: 0.28% → 0.3% (+0.02%)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
G
Gainplan
Bloomfield Hills,
Michigan
|
+$650K |
| 2 |
Morgan Stanley
New York
|
+$407K |
| 3 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
+$264K |
| 4 |
EWA
Exencial Wealth Advisors
Oklahoma City,
Oklahoma
|
+$243K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$180K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$4.76M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.42M |
| 3 |
Jane Street
New York
|
-$2.27M |
| 4 |
HJMC
Hellman Jordan Management Company
Quincy,
Massachusetts
|
-$1.95M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$591K |
LABU Hedge Fund Activity: Q2 2020 in Review
20 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q2 2020, worth a combined $22.5M — up 41% from $15.9M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new LABU positions and 7 closed out — a net gain of 2 holders — while 2 added to existing stakes and 7 trimmed.
The largest buyer was Gainplan, opening a new position worth an estimated $650K. The largest seller was Citigroup, exiting entirely with an estimated $4.76M sold.
- 20 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q2 2020, up from 19 in Q1 2020.
- Funds reported $22.5M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q2 2020, up 41% quarter-over-quarter.
- 9 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q2 2020 and 7 closed out, a net change of +2 holders.
- The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q2 2020 was Gainplan, an estimated $650K added.
- The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q2 2020 was Citigroup, an estimated $4.76M sold.
Based on aggregated 13F filings for Q2 2020.